This thesis set out to examine whether the demographic diversity of participants in clinical trials involving allogeneic stem cell transplant recipients matched the diversity of the actual allogeneic recipient population overall. It is important that clinical trials study new therapies in a population that represents characteristics of the overall treatment population in order to gain accurate safety and efficacy data. The actual diversity of the allogeneic transplant population was determined using data reported to the Center for International Blood & Marrow Transplant Research (CIBMTR) registry. Then, a comprehensive literature review was conducted to identify the population of allogeneic transplant recipients who took part in clinical research. In comparing the two populations, it was determined that women are well-represented in allogeneic transplant trials, while non-white minorities remain underrepresented. These findings demonstrate that there is more work be done in order to ensure everyone has equal access to clinical trials.
","abstract_html":"<p>This thesis set out to examine whether the demographic diversity of participants in clinical trials involving allogeneic stem cell transplant recipients matched the diversity of the actual allogeneic recipient population overall. It is important that clinical trials study new therapies in a population that represents characteristics of the overall treatment population in order to gain accurate safety and efficacy data. The actual diversity of the allogeneic transplant population was determined using data reported to the Center for International Blood & Marrow Transplant Research (CIBMTR) registry. Then, a comprehensive literature review was conducted to identify the population of allogeneic transplant recipients who took part in clinical research. In comparing the two populations, it was determined that women are well-represented in allogeneic transplant trials, while non-white minorities remain underrepresented. These findings demonstrate that there is more work be done in order to ensure everyone has equal access to clinical trials.</p>","abstract_has_math":false,"creators":["Churay, Tracey"],"institution":null,"degree_name":"Master of Science (MS)","degree_level":"Open Access Thesis","degree_discipline":"Health Sciences","degree_department":null,"school":null,"contributors":["Irwin Martin","John Magenau"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2016,"date_issued":"2016-01-01T08:00:00Z","date_published":"2016-01-01T08:00:00Z","updated_at":"2026-07-24T02:17:13Z","subjects":["Clinical Research","Medicine and Health Sciences"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://commons.emich.edu/theses/806","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Irwin Martin","John Magenau"]},{"key":"dc:creator","label":"Author","values":["Churay, Tracey"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2018-03-08T08:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Health Sciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Open Access Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science (MS)"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Clinical Research","Medicine and Health Sciences"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://commons.emich.edu/theses/806"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["This thesis set out to examine whether the demographic diversity of participants in clinical trials involving allogeneic stem cell transplant recipients matched the diversity of the actual allogeneic recipient population overall. It is important that clinical trials study new therapies in a population that represents characteristics of the overall treatment population in order to gain accurate safety and efficacy data. The actual diversity of the allogeneic transplant population was determined using data reported to the Center for International Blood & Marrow Transplant Research (CIBMTR) registry. Then, a comprehensive literature review was conducted to identify the population of allogeneic transplant recipients who took part in clinical research. In comparing the two populations, it was determined that women are well-represented in allogeneic transplant trials, while non-white minorities remain underrepresented. These findings demonstrate that there is more work be done in order to ensure everyone has equal access to clinical trials.
"]},{"key":"dc:title","label":"Title","values":["The diversity of participants in clinical trials involving allogeneic hematopoietic stem cell transplant recipients"]}]}],"canonical_facts":{"dc:contributor":["Irwin Martin","John Magenau"],"dc:creator":["Churay, Tracey"],"dc:date.available":["2018-03-08T08:00:00Z"],"dc:description.abstract":["This thesis set out to examine whether the demographic diversity of participants in clinical trials involving allogeneic stem cell transplant recipients matched the diversity of the actual allogeneic recipient population overall. It is important that clinical trials study new therapies in a population that represents characteristics of the overall treatment population in order to gain accurate safety and efficacy data. The actual diversity of the allogeneic transplant population was determined using data reported to the Center for International Blood & Marrow Transplant Research (CIBMTR) registry. Then, a comprehensive literature review was conducted to identify the population of allogeneic transplant recipients who took part in clinical research. In comparing the two populations, it was determined that women are well-represented in allogeneic transplant trials, while non-white minorities remain underrepresented. These findings demonstrate that there is more work be done in order to ensure everyone has equal access to clinical trials.
"],"dc:identifier":["https://commons.emich.edu/theses/806"],"dc:subject":["Clinical Research","Medicine and Health Sciences"],"dc:title":["The diversity of participants in clinical trials involving allogeneic hematopoietic stem cell transplant recipients"],"thesis:degree_discipline":["Health Sciences"],"thesis:degree_level":["Open Access Thesis"],"thesis:degree_name":["Master of Science (MS)"]},"updated_at":"2026-07-24T02:17:13Z"}